Last reviewed · How we verify

Cox-2 — Competitive Intelligence Brief

Cox-2 (Cox-2) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cox-2 selective inhibitor (NSAID). Area: Rheumatology / Pain Management / Inflammation.

marketed Cox-2 selective inhibitor (NSAID) Cyclooxygenase-2 (Cox-2) Rheumatology / Pain Management / Inflammation Small molecule Live · refreshed every 30 min

Target snapshot

Cox-2 (Cox-2) — First Affiliated Hospital Xi'an Jiaotong University. Cox-2 inhibitors selectively block cyclooxygenase-2 enzyme to reduce prostaglandin production and inflammation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cox-2 TARGET Cox-2 First Affiliated Hospital Xi'an Jiaotong University marketed Cox-2 selective inhibitor (NSAID) Cyclooxygenase-2 (Cox-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cox-2 selective inhibitor (NSAID) class)

  1. First Affiliated Hospital Xi'an Jiaotong University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cox-2 — Competitive Intelligence Brief. https://druglandscape.com/ci/cox-2. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: